Literature DB >> 16891042

Neurotensin: role in psychiatric and neurological diseases.

Ricardo Cáceda1, Becky Kinkead, Charles B Nemeroff.   

Abstract

Neurotensin (NT), an endogenous brain-gut peptide, has a close anatomical and functional relationship with the mesocorticolimbic and neostriatal dopamine system. Dysregulation of NT neurotransmission in this system has been hypothesized to be involved in the pathogenesis of schizophrenia. Additionally, NT containing circuits have been demonstrated to mediate some of the mechanisms of action of antipsychotic drugs, as well as the rewarding and/or sensitizing properties of drugs of abuse. NT receptors have been suggested to be novel targets for the treatment of psychoses or drug addiction.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16891042     DOI： 10.1016/j.peptides.2006.04.024

Source DB:  PubMed          Journal:  Peptides        ISSN： 0196-9781            Impact factor:   3.750


  43 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

2.  Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2.

Authors:  Moonnoh R Lee; David J Hinton; Sencan S Unal; Elliott Richelson; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2010-10-06       Impact factor: 3.455

3.  Neurotensin reduces glutamatergic transmission in the dorsolateral striatum via retrograde endocannabinoid signaling.

Authors:  Henry H Yin; Louise Adermark; David M Lovinger
Journal:  Neuropharmacology       Date:  2007-06-22       Impact factor: 5.250

4.  C4ORF48, a gene from the Wolf-Hirschhorn syndrome critical region, encodes a putative neuropeptide and is expressed during neocortex and cerebellar development.

Authors:  Sabine Endele; Claudia Nelkenbrecher; Annegret Bördlein; Stefanie Schlickum; Andreas Winterpacht
Journal:  Neurogenetics       Date:  2011-02-02       Impact factor: 2.660

Review 5.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

6.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Eur J Neurosci       Date:  2018-02-28       Impact factor: 3.386

7.  Neurotensinergic augmentation of glutamate release at the perforant path-granule cell synapse in rat dentate gyrus: Roles of L-Type Ca²⁺ channels, calmodulin and myosin light-chain kinase.

Authors:  Haopeng Zhang; Hailong Dong; Saobo Lei
Journal:  Neuropharmacology       Date:  2015-04-02       Impact factor: 5.250

Review 8.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

9.  Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

10.  Conformational Changes in Tyrosine 11 of Neurotensin Are Required to Activate the Neurotensin Receptor 1.

Authors:  Fabian Bumbak; Trayder Thomas; Billy J Noonan-Williams; Tasneem M Vaid; Fei Yan; Alice R Whitehead; Shoni Bruell; Martina Kocan; Xuan Tan; Margaret A Johnson; Ross A D Bathgate; David K Chalmers; Paul R Gooley; Daniel J Scott
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.